CD226 antibody

Catalog No. ABIN119799

Product Details anti-CD226 Antibody

Target: CD226

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD226 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP)

Specificity: This antibody recognises CD226. Clone DX11 is reported to inhibit T- and NK cell mediated cytotoxicity against tumour cell targets and to block TNF alpha and IFN gamma secretion by alloantigen-specific T-cells. We recommend the use of SM2023A for funtional studies.

Purification: Affinity chromatography on Protein G

Immunogen: Human cytotoxic T lymphocyte clone. Spleen cells from immunised BALB/c mouse were fused with cells of the Sp2/0 myeloma cell line.

Clone: DX11

Isotype: IgG1

Application Details

Application Notes: Flow Cytometry: 1/25 - 1/100, Use 10 μL of the suggested working dilution to label 1 x 10^6 cells in 100 μL. Immunoprecipitation.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: PBS, pH 7.4 containing 0.09 % Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for CD226

Target: CD226

Alternative Name: CD226 / DNAM1 (CD226 Products)

Background: CD226 is a 65kD glycoprotein, also known as DNAM1 (DNAX accessory molecule-1). CD226 is broadly expressed on T-cells, NK cells, platelets, monocytes and a subset of B cells. CD226 is also expressed by a subset of CD3 positive thymocytes.Synonyms: DNAM-1, DNAX accessory molecule 1

Gene ID: 10666

NCBI Accession: NP_006557

UniProt: Q15762

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints